Loading...
Market
What will be the outcome of initial clinical trials for vortioxetine as a glioblastoma treatment by September 30, 2025?
2
Resolution / Starting Odds
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial halted or delayed • 25%
Published clinical trial results, ETH Zurich announcements, or reputable medical journals
Story
£40 Antidepressant Vortioxetine Found Effective Against Glioblastomas in ETH Zurich Study
Sep 20, 2024, 10:29 AM
Researchers have discovered that vortioxetine, a widely available antidepressant costing £40, shows unexpected effectiveness in treating glioblastomas, the most common and aggressive type of brain tumour. Studies conducted in cell cultures and mice by ETH Zurich and other research teams demonstrated that the drug can shrink tumours and kill tumour cells. This breakthrough suggests that vortioxetine could be repurposed to combat glioblastomas, offering a potentially new treatment avenue for this deadly brain cancer.
View original story
Similar markets
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Complete Response (CR) • 25%
Partial Response (PR) • 25%
Stable Disease (SD) • 25%
Progressive Disease (PD) • 25%
New drug approval • 25%
Major clinical trial success • 25%
New treatment guidelines • 25%
Other • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results published • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Complete Response • 25%
Partial Response • 25%
Stable Disease • 25%
Progressive Disease • 25%
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial not completed • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
Trial discontinued • 25%
Positive outcome with significant efficacy • 25%
Mixed outcome with limited efficacy • 25%
Negative outcome with no efficacy • 25%
Trial terminated early due to safety concerns • 25%
Successful with no major adverse effects • 25%
Successful with minor adverse effects • 25%
Unsuccessful due to lack of efficacy • 25%
Unsuccessful due to major adverse effects • 25%
Approved • 25%
Not Approved • 25%
Approval Pending • 25%
Withdrawn • 25%